Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Clinical evidence

APeX-2

15 evidence topics · 4 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Randomized and treated populations
Description of analysis sets
Results
Participant disposition
Treatment exposure
Baseline characteristics
Median baseline attack rate during the prospective run-in period
Efficacy results
Monthly attack rates during the 24-week comparison
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

The trial randomized 121 participants at 40 sites in 11 countries and treated 120: 41 received berotralstat 110 mg, 40 received berotralstat 150 mg, and 39 received placebo. Eligibility required “at least two investigator-confirmed attacks” during the run-in period, and the median baseline attack rate was 2.9 attacks per month. Efficacy was analyzed in the intent-to-treat population with a “negative binomial regression model”. The comparison does not describe outcomes over longer treatment, and groups of 39 to 41 participants limit precision for uncommon adverse events. No health-related quality of life result for this trial was identified. Berotralstat was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, and observation periods can affect the reported attack rates.